MCRB

Seres Therapeutics Inc

• PUBT·05/12 11:05

  Seres Therapeutics presents at H.C. Wainwright BioConnect investor conference

• TipRanks·05/06 11:31

  Seres Therapeutics (MCRB) Gets a Buy from Canaccord Genuity

• Reuters·05/05 11:18

  Seres Therapeutics reports Q1 net loss

• Seeking Alpha·05/05 11:15

  Seres Therapeutics GAAP EPS of -$2.08 misses by $0.20, revenue of $0.36M

• Benzinga·05/05 11:14

  Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

• PUBT·05/05 11:06

  Seres Q1 FY26 net loss turns to USD 19.9 million; revenue at USD 358,000

• Reuters·05/05 11:00

  BRIEF-Seres Therapeutics Q1 EPS USD -2.08

• Dow Jones·05/05 11:00

  Press Release: Seres Therapeutics Reports First -2-

• Dow Jones·05/05 11:00

  *Seres Therapeutics 1Q Loss $19.9M >MCRB

• Dow Jones·05/05 11:00

  Press Release: Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

• Benzinga·05/04 11:32

  Seres Therapeutics Presents New Preclinical Data To Support Design, Potential Of SER-603 Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease

• Benzinga·05/04 11:06

  Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026

• PUBT·05/04 11:02

  Seres presents preclinical DDW data supporting IBD candidate SER-603

• TipRanks·04/20 11:22

  Seres Therapeutics announces three presentations at 2026 ESCMID congress

• Benzinga·04/20 11:07

  Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21